Gene line capable of distinguishing physiological expression and pathological expression of gene

By designing the oncogene activation and inhibitory receptors in the gene circuit, and automatically identifying and regulating gene expression, the problem of difficult to distinguish between physiological and pathological expression in the prior art is solved, and precise distinction and treatment of gene expression is achieved. Reduce side effects and improve treatment effect.

CN118956962APending Publication Date: 2024-11-15SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410859123.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to distinguish and accurately intervene in physiological and pathological gene expression, resulting in unnecessary intervention of targeted therapy on normal cells, causing side effects, and lack of strategies or drugs that can distinguish physiological and pathological expression, affecting the disease. Accurate treatment.

Method used

A gene circuit was designed that includes oncogene activation and inhibitory receptors, which uses specific DNA sequences and transcriptional activation/repression elements to automatically identify and regulate the expression of target genes, distinguishing gene expression in tumor cells and normal cells. , achieve precise intervention.

Benefits of technology

It realizes accurate distinction and treatment of gene expression, reduces damage to normal cells, improves treatment effect, reduces side effects, promotes personalized medical care, improves treatment success rate, and promotes medical research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956962A_ABST
    Figure CN118956962A_ABST
Patent Text Reader

Abstract

The invention discloses a gene line capable of distinguishing physiological expression and pathological expression of a gene. The gene line comprises a cancer-promoting gene activation receptor and a cancer-promoting gene inhibition receptor. The cancer-promoting gene activation receptor contains a cancer-promoting gene activation promoter and a target gene, and the cancer-promoting gene activation receptor is used for promoting the expression of the target gene. The cancer-promoting gene inhibitory receptor contains a cancer-promoting gene inhibitory promoter and an inhibitory element that inhibits the expression of a target gene, and is for inhibiting the expression of the target gene. The cancer-promoting gene activating receptor and the cancer-promoting gene inhibiting receptor are used for recognizing and sensing the physiological expression of the cancer-promoting gene in normal cells or the pathological expression of the cancer-promoting gene in tumor cells and activating or inhibiting the expression of a target gene according to the expression quantity of the cancer-promoting gene, so that a precise intervention / treatment effect is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a gene circuit and a therapeutic system capable of distinguishing between physiological expression and pathological expression of a specific gene. Background Art

[0002] Gene expression refers to the transcription and translation of genes in organisms, which produces functional proteins or RNA molecules. The regulation of gene expression is a complex and orderly process of multiple cell recognition and signal transduction pathways, which can be divided into physiological and pathological categories.

[0003] Physiological gene expression regulation refers to a regulatory process in which the gene expression level is in a dynamic equilibrium state in multiple aspects such as cell growth, differentiation, and function in normal organisms. This type of regulation often involves many pathways, including transcription factors, transcription initiation factors, small molecule proteins, and miRNA. Among them, transcription factors refer to protein molecules that regulate genes and can activate or inhibit the transcription of specific genes by binding to transcription regulatory elements (TREs) on DNA sequences. There are about 2,000 known transcription factors, including open chromatin structural factors such as the SWI / SNF complex and Histone modifying enzymes, the MYC transcription factor family including c-MYC, L-MYC, and N-MYC, etc. These transcription factors are key regulators of cell proliferation, cell differentiation, cell cycle, and metabolism.

[0004] Pathological gene expression regulation refers to the regulatory process involved in gene expression levels that are different from normal levels in certain disease states. Abnormal gene expression in some disease states is often caused by certain factors such as viral infection, damaged cells and complications.

[0005] Physiological and pathological gene expression regulation is a key link in the process of cell physiological and pathological changes, and plays a vital role in maintaining life, preventing diseases and treating diseases. At present, most pathogenic factors are expressed in both normal and abnormal cells, and their physiological expression in normal cells is crucial to maintaining normal cell life activities. Once these important factors are abnormally overexpressed, they will cause abnormal cell function or even deterioration. However, the current mainstream targeted therapy strategy indiscriminately targets pathogenic factors in all cells. Although it intervenes in abnormal cells to a certain extent, it will also cause unnecessary intervention in normal cells, which may damage the function of normal cells and cause adverse reactions. Taking the transcription factor c-MYC as an example, c-MYC is involved in a variety of biological processes, such as cell cycle regulation, cell proliferation and apoptosis regulation. In normal cells, the expression level of c-MYC is usually low (physiological expression), but in many tumors, the c-MYC gene is overexpressed (pathological expression). Overexpressed c-MYC is closely related to the occurrence and development of tumors. Therefore, c-MYC is considered to be a promising target for tumor treatment. It is worth noting that despite the key role of c-MYC in tumorigenesis, its value as a therapeutic target remains largely unexplored, mainly due to the difficulty in distinguishing pathological from physiological c-MYC expression. Functionally, c-MYC exerts physiological and pathological effects by selectively binding to target promoters. Although c-MYC is highly expressed in most tumors, there is still a physiological low amount of c-MYC expression in normal cells. Therefore, if c-MYC expression in all cells is indiscriminately inhibited, it will also cause unnecessary toxic side effects to normal cells, which may affect the proliferation, differentiation or viability of these cells, causing side effects such as bone marrow suppression, adverse reactions of the digestive system, and decreased immune system function.

[0006] However, no strategy or drug has yet been developed that can distinguish between physiological and pathological expression, and there is still a long way to go to achieve precise treatment of diseases. If we can successfully develop a strategy to distinguish between physiological and pathological gene expression, achieve precise distinction and treatment of gene expression, and shift from a "one-size-fits-all" treatment model to an individualized, efficient, and low-toxic treatment paradigm, it will be of great significance to improving human health and prolonging life. Summary of the invention

[0007] One of the purposes of the present invention is to provide a gene circuit that can distinguish the physiological expression and pathological expression of genes and perform targeted intervention.

[0008] Another object of the present invention is to provide a treatment system, which can be used for diagnosis or treatment of diseases.

[0009] The above-mentioned purpose of the present invention is achieved by the following technical means:

[0010] In one aspect, the present invention provides a gene circuit that can distinguish between physiological and pathological gene expression, comprising the following components:

[0011] (1) An oncogene activating receptor (activator), which is used to promote the expression of target genes (genes of interest, GOIs); it contains (a) an activating promoter of an oncogene, wherein the activating promoter of an oncogene contains at least a DNA sequence specifically binding to an oncogene protein and a promoter core sequence for transcriptional activation arranged in cis; and (b) a target gene, wherein the target gene contains at least a CDS sequence for target gene expression and a binding sequence for a target gene inhibitory element arranged in cis;

[0012] (2) An oncogene suppressor, which is used to suppress the expression of a target gene; it contains (a) an oncogene suppressor promoter, wherein the oncogene suppressor promoter contains at least a DNA sequence that specifically binds to an oncogene protein and a promoter core sequence that suppresses transcription, arranged in cis; and (b) an inhibitory element that suppresses the expression of the target gene.

[0013] The gene circuit of the present invention can automatically identify and exert its efficacy in response to the pathological high expression of oncogenes in tumor cells and the physiological expression in normal cells. Specifically, in tumor cells with high expression of oncogenes, the oncogene activation receptor (activator) will be in an active state, because the oncogene protein binds to the complementary pairing region on the activation promoter of the oncogene, making the transcriptionally activated promoter in an active state, thereby promoting the massive expression of downstream target genes, while the oncogene inhibitory receptor (suppressor) is only in a weakly activated state at this time, ultimately causing the target gene to be expressed in large quantities to play a role in regulating cells. In normal cells with low expression of oncogenes, the oncogene activating receptor (activator) is in a weakly activated state, while the oncogene inhibitory receptor (suppressor) is in an active state. This is because the transcriptionally inhibited promoter drives the expression of a large number of inhibitory elements, and the inhibitory elements specifically bind to the binding sequences of the inhibitory elements in the target gene mRNA in the oncogene activating receptor, thereby inhibiting the target gene and making it basically unexpressed, ultimately reducing the impact of the target gene on normal cells with low expression of oncogenes and achieving precision treatment.

[0014] In some embodiments, the cancer-promoting gene is selected from transcription factor genes. Transcription factors are a class of protein molecules that regulate gene expression, which activate or inhibit the transcription of specific genes by binding to transcription regulatory elements (TRE) on DNA sequences.

[0015] In some specific embodiments, the oncogene is selected from one or more of c-MYC, N-MYC, L-MYC, E2F1, E2F2, E2F3, CREB, NF-κB, STAT (signal transducers and activators of transcription), AP-1 (activator protein 1), bzip and HMG.

[0016] In some embodiments, the target gene is selected from tumor immune activation cytokine genes, immune activation receptor / ligand genes, immune activation antibody genes, cytotoxic protein genes, or one or more combinations thereof of functional fragments. Among them, tumor immune activation cytokines such as lymphotoxin and interferon can activate the body's immune system, making it more effective in identifying and attacking tumor cells, and cytotoxic protein genes have the ability to directly kill tumor cells. For example, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is an important cytotoxic protein that can transmit inhibitory signals to T cells, thereby playing a role in immune regulation.

[0017] In some specific embodiments, the target gene is selected from CCL5, anti-PD1, anti-CTLA-4, IL21, IL2, IL-15, IL-7, IL-18, IL-12, GM-CSF, OX40L, anti-OX40, IFN-γ, TNF-α, CD137, anti-CD3, anti-CD28, or one or more combinations thereof.

[0018] In a preferred embodiment, the target gene is selected from a combination of anti-CD3 and anti-CD28, in particular a combination of single-chain variable region fragments (scFv): a combination of anti-CD3-scFv and anti-CD28-scFv.

[0019] In some embodiments, the inhibitory element is selected from one or more of siRNA, shRNA, miRNA, CRISPR-Cas9, CRISPR-Cas12a, CRISPR-Cas12j, CRISPR-Cas12f, CRISPR-Cas13a, CRISPR-Cas13b and CRISPR-Cas13d. These inhibitory elements can achieve the expression inhibition of the target gene by specifically matching the binding sequence of the inhibitory element in the target gene mRNA transcribed from the oncogene activation receptor.

[0020] In a more preferred embodiment, in order to enable the oncogene inhibitory receptor to effectively counteract the unnecessary expression of the target gene in the gene circuit when the oncogene is underexpressed, we designed a unique inhibitory element - an inhibitory element based on aRNA (artificial RNA), the gene sequence of which is located at the 3' end of the inhibitory promoter, and contains a hammerhead ribozyme region (ribozyme) at the 3' end and a miRNA at the 5' end. After transcription, the aRNA binds to the binding sequence of the target gene inhibitory element transcribed in the oncogene activating receptor to achieve mRNA degradation of the target gene.

[0021] In a more preferred embodiment, in the oncogene activation receptor, the binding sequence of the target gene inhibitory element is a uniquely designed aRNA-binding site (abbreviated as "aRNA-BS"). The gene sequence of the aRNA-binding site (aRNA-BS) is located at the 3' end of the target gene CDS sequence, and it contains a 5' hammerhead ribozyme and a 3' miRNA binding sequence.

[0022] The aRNA and aRNA-BS constitute a self-cleavage system, which can effectively degrade the mRNA of the target gene without producing off-target effects. That is, the self-cleavage system comprises an inhibitory element-aRNA located in the inhibitory receptor of the oncogene, and a unique binding site aRNA-BS matching the aRNA located in the oncogene activating receptor, and the aRNA-BS is the binding sequence of the inhibitory element in the target gene driven by the oncogene activating promoter in the oncogene activating receptor.

[0023] When the transcription products of the self-cleavage system aRNA and aRNA-BS are complementary and paired, the ribozyme designed on the aRNA / aRNA-BS will be activated and degraded. At this time, the miRNA designed on the aRNA can be separated from the ribozyme structure from the original aRNA design, so that the mRNA molecule where the miRNA binding sequence is located can be further hydrolyzed. In summary, after the designed aRNA binds to the aRNA-BS, it will activate and induce the aRNA itself to degrade the target gene mRNA where the aRNA-BS is located three times, degrading the target gene mRNA, and then efficiently inhibiting the expression of the target gene, thereby offsetting the unnecessary expression of the target gene in the gene circuit when the oncogene is lowly expressed.

[0024] In some preferred embodiments, there are multiple aRNA-BSs (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more, etc.) encoded in tandem in the 3' cassette encoding the target genes (GOIs).

[0025] Compared with common siRNA inhibitory elements (inhibition rate 79%), the specifically designed inhibitory system - the self-cleavage system of the present invention exhibits a better inhibitory effect on the target gene (inhibition rate 96%). After the aRNA-BS of the self-cleavage system reprograms the mRNA of the target gene, the expression efficiency of the target gene is reduced to a negligible level, and there is almost no off-target expression in different types of cells.

[0026] In order to amplify the expression of the target gene driven by the high expression of oncogenes in the oncogene-activated receptor, as a preferred embodiment, the oncogene-activated receptor of the present invention further comprises a target gene expression amplification system (GOI expression amplification system, GEAS).

[0027] Specifically, the target gene expression amplification system (GEAS) contains a gene sequence of a strong transcription activator and a binding site of the strong transcription activator. The gene sequence of the strong transcription activator is connected to the 3' end of the target gene through the gene sequence of the self-hydrolyzed polypeptide, and the binding site of the strong transcription activator is located at the 5' end of the activation promoter of the cancer-promoting gene.

[0028] The strong transcription activator expressed by the gene sequence of the strong transcription activator can be separated from the polypeptide sequence of the target gene under the action of the self-hydrolyzed polypeptide, and then bind to the strong transcription activator binding site at the 5' end of the activating promoter of the oncogene, and recruit various auxiliary factors to form a transcription initiation complex, thereby enhancing the transcription activity of the activating promoter of the oncogene, and ultimately enhancing the expression of the target gene.

[0029] In some specific embodiments, the strong transcriptional activator is selected from one or more of KLF6, VP64, VP16, VPR, or partial domains thereof.

[0030] In some preferred embodiments, the strong transcriptional activator consists of partial domains of KLF6 and VP64.

[0031] In some specific embodiments, the self-hydrolyzable polypeptide is selected from one or more of T2A, P2A, E2A and F2A. The selection of the self-hydrolyzable polypeptide is not particularly limited, as long as it can separate the strong transcription activator from the target gene polypeptide.

[0032] In a preferred embodiment, the gene circuit contains both a self-cleavage system and an expression amplification system, which contains the following components:

[0033] (1) Oncogene activation receptors (activators), which contain a strong transcription activator binding sequence, an oncogene activation promoter, a target gene, a hydrolyzed polypeptide, a strong transcription activator, and an aRNA-BS sequence arranged in cis;

[0034] (2) Oncogene suppressor, which contains the inhibitory promoter of the oncogene and the aRNA sequence arranged in cis.

[0035] The oncogene activating sensor and the oncogene inhibiting sensor are located in the same gene circuit or in different gene circuits.

[0036] In one embodiment of the present invention, the oncogene activating sensor and the oncogene inhibitory sensor are located in the same gene circuit.

[0037] In another embodiment of the present invention, the oncogene activating sensor and the oncogene inhibiting sensor are located in different gene circuits.

[0038] In another aspect, the present invention provides mRNA produced by transcription of the above gene circuit.

[0039] In another aspect, the present invention provides a protein expressed by the above gene circuit.

[0040] In another aspect, the present invention provides an expression vector containing the above gene circuit.

[0041] In some embodiments, the expression vector is selected from one or more of plasmid, phagemid, cosmid, baculovirus, baculovirus shuttle vector, bacterial expression vector, yeast expression vector and viral vector expression vector. These vectors are expression vectors, which can effectively transcribe and translate the target gene cloned into the vector in a specific host cell, thereby producing a target protein or RNA molecule.

[0042] In another aspect, the present invention provides a therapeutic system comprising the above gene circuit and a delivery vector for delivering the gene circuit.

[0043] In some embodiments, the delivery vector is selected from one or more of a viral delivery vector, a nanoparticle vector, and a vesicle.

[0044] In some embodiments, the nanoparticle carrier can be selected from liposomes, virus-like particles, and the like.

[0045] In some preferred embodiments, the delivery vector is selected from a viral delivery vector, specifically, the viral delivery vector is selected from an adeno-associated virus (AAV) vector, a chimeric adeno-associated virus vector, an adenovirus vector, a retrovirus vector, a lentivirus vector, a DNA virus vector, a herpes simplex virus vector, a baculovirus vector or any mutant or derivative thereof.

[0046] In some embodiments, the therapeutic system is administered by one or more of in situ tumor injection, in situ perfusion, oral administration, inhalation, subcutaneous injection, intramuscular injection, and intravenous injection.

[0047] In some preferred embodiments, the therapeutic system is administered by in situ injection or in situ perfusion into the tumor.

[0048] In another aspect, the present invention provides the use of the above-mentioned gene circuit, or mRNA, or protein, or expression vector in disease diagnosis or treatment.

[0049] In some embodiments, the disease is selected from a tumor.

[0050] In some preferred embodiments, the tumor is selected from one or more of esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer, gallbladder cancer, islet cell tumor, lung cancer, pleural mesothelioma, bladder cancer, kidney cancer, prostate cancer, testicular cancer, ovarian cancer, cervical cancer, endometrial cancer, vaginal cancer, leukemia, lymphoma, multiple myeloma, brain tumor, spinal cord tumor, thyroid cancer, parathyroid tumor, insulinoma, melanoma, basal cell carcinoma, squamous cell carcinoma, osteosarcoma, Ewing's sarcoma, liposarcoma, leiomyosarcoma, oral cancer, nasopharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, thyroid cancer, breast cancer, eye tumor, and heart tumor.

[0051] One embodiment of the present invention has the following beneficial effects:

[0052] (1) The gene circuit of the present invention achieves the distinction between physiological and pathological gene expression and precise intervention, which has the following significance:

[0053] Improve treatment effects: By accurately identifying and intervening only on pathologically expressed genes, the root causes of the disease can be eliminated more effectively, damage to normal cells and tissues can be reduced, and the targeting and effectiveness of treatment can be improved;

[0054] Reduce side effects: Avoiding or reducing unnecessary interventions on genes important for physiological functions can significantly reduce side effects during treatment and improve patients’ quality of life and comfort during treatment;

[0055] Promote personalized medicine: Each person's gene expression profile is unique. Accurately distinguishing between pathological and physiological expressions will help develop personalized treatment plans and tailor treatment strategies to each patient's specific circumstances.

[0056] Preventing disease progression: Timely identification and intervention of pathological gene expression can effectively prevent or delay the development of the disease, especially in diseases such as cancer, where early and precise treatment is crucial to prevent metastasis and recurrence;

[0057] Improve treatment success rate: Precision treatment can improve the success rate of treatment and reduce attempts at ineffective or inefficient treatments, which is a great improvement in resource allocation and cost-effectiveness;

[0058] Promoting medical research: A deeper understanding of pathological and physiological gene expression will promote basic science research, help scientists discover new drug targets and therapeutic mechanisms, and accelerate medical progress.

[0059] (2) The specially designed self-cleavage system of the present invention exhibits a better inhibitory effect on the target gene (inhibition rate of 96%). After the aRNA-BS of the self-cleavage system reprograms the mRNA of the target gene, the expression efficiency of the target gene is reduced to a negligible level, and there is almost no off-target expression in different cells.

[0060] (3) The target gene expression amplification system (GEAS) of the present invention can efficiently drive the expression of the target gene when the oncogene is highly expressed, thereby maximizing the effect of the target gene and exerting an efficient therapeutic effect in cells with highly expressed oncogenes. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 It is an activating promoter receptor (activator) and its effect: (a) Schematic diagram of the c-MYC-activator structure; (b) 293t-MYC GFP cultured with 1μg / ml tetracycline has a high relative expression level, c-MYC is highly expressed (high-myc), while 293t-MYC transfected with c-MYC siRNA has a low expression (low-myc); (c) The response of c-MYC-activator-GFP in 293t cells to different expression levels of c-MYC. ***p<0.001

[0062] Figure 2It is a suppressor of the inhibitory promoter and its effects: (a) Schematic diagram of the c-MYC-repressor structure; (b) 293t-MYC cultured with 1μg / ml tetracycline has high relative RFP expression, high c-MYC expression (high-myc), while 293t-MYC transfected with c-MYC siRNA has low expression (low-myc); (c) c-MYC-repressor-RFP in 293t cells responds to different expression levels of c-MYC. ***p<0.001

[0063] Figure 3 Figure 2 is the dose response of activating and inhibitory receptors to c-MYC in 293t cells: (a) The dose response of activating receptor c-MYC-activator-GFP to c-MYC; (b) The dose response of inhibitory receptor c-MYC-repressor-RFP(b) to c-MYC. The c-MYC copy number is plotted based on the mean fluorescence intensity and calculated based on the RT-qPCR results with wild-type 293t as the control; the figure shows the results of independent experiments EP1, EP2, and EP3.

[0064] Figure 4 It is a schematic diagram of the self-cleavage system aRNA / aRNA-BS.

[0065] Figure 5 The schematic diagram of the structural design and working principle of 3'tailed mitron. (a) Schematic diagram of the aRNA precursor structure, where R = A or G; (b) Schematic diagram of the aRNA structure; (c) Schematic diagram of the workflow of aRNA / aRNA-BS in cells.

[0066] Figure 6 is the inhibition efficiency of different vectors; data are expressed as mean ± standard deviation, and the significance was determined by two-tailed one-way ANOVA, NS = not significant.

[0067] Figure 7 is the gene circuit c-MSC; (a) Design of c-MYC-induced cMSC (c-MYC sensing circuit) to activate GFP expression, the expression of the 3′ cassette encoding GFP with 5′ aRNA binding site is driven by the c-MYC activator, and the aRNA expression module is expressed using a c-MYC blocker; (b) Preliminary cMSCs were tested for GFP expression in low, medium, and high c-MYC expressing cells, and the percentage of GFP+ cells was measured using flow cytometric analysis and is shown on the right; (c) Dose response of cMSCs-GFP to c-MYC in 293T cells.

[0068] Figure 8This is an evaluation of the initial construction of a gene circuit platform based on c-MYC recognition to identify different endogenous cMYC expressions: (a) 293t-MYC c-MYC high expression (high-myc) cultured with 1μg / ml tetracycline, while 293t-MYC c-MYC low expression (low-myc) transfected with siMYC. High-myc cells transfected with cMSC-driven GFP expressed 27 times more GFP than low-myc cells; (b) cMSC dose response to 293t cell c-MYC; (c) T24, UMUC3 and Hela cells initially transfected with cMSC were 23.6 times, 20.5 times and 24.2 times that of SVHUC1, respectively.

[0069] Fig. 9 It is the activation effect of different strong transcription activators.

[0070] Fig.10 The following are schematic diagrams of the structure of the expression amplification system containing different strong transcriptional activators and their effects: (a) Schematic diagram of the expression amplification system design. The expression amplification system consists of a 5' GFP expression cassette and a 3' transcriptional activation subdomain (GAL4-VP64, KLF6 and KLFa, respectively) separated by the T2A coding region. The expression amplification system is driven by TetO expression redesigned with GAL4-BS, KLF6-BS and KLFa-BS, respectively. (b) The dose response of GFP expression in three groups of 293T cells to tetracycline concentration. The data are expressed as mean ± standard deviation, and the significance was analyzed by two-tailed one-way ANOVA, *p<0.05.

[0071] Fig.11 This is a schematic diagram of the gene circuit structure that contains both a self-cleavage system and a strong transcription activator.

[0072] Fig.12 It is the transcriptional activation efficiency of the target gene by a gene circuit containing both a self-cleavage system and a strong transcriptional activator.

[0073] Fig.13 It is the transcriptional activation efficiency of gene circuits containing both self-cleavage systems and strong transcriptional activators in different cancer cell types.

[0074] Fig.14 The expression efficiency of cMSCs in human tumor xenograft mouse models mediated by AAV is shown as follows: (a) Relative expression level of c-MYC in U2OS and T24 tumor tissues; (b) Quantitative analysis of GFP expression; (c) GFP expression was detected in U2OS and T24 tumors infected with AAV-mediated cMSC-GFP. Data are expressed as mean ± standard deviation, and significance was determined by two-tailed Student's t test, ***P<0.001.

[0075] Fig.15 The expression efficiency of cMSCs mediated by AAV in human organ models: (a) Quantification of MYC expression in three organoids; (b) Quantification of GFP expression in human bladder cancer organoids; (c) representative images; data are expressed as mean ± standard deviation, and significance was analyzed by two-tailed one-way ANOVA, ***P<0.001.

[0076] Fig.16 This is a schematic diagram of the target gene expression structure for the expression of cMSC-driven immune combination factors mediated by AAV.

[0077] Fig.17 The therapeutic effect of AAV-mediated cMSC-driven immune combination factors in mouse xenograft tumor models: Representative images of tumors in each group and statistical graphs of tumor weight. Data are presented as mean ± sds (n = 5), and significance was analyzed by two-tailed one-way ANOVA, *p < 0.05, **p < 0.01.

[0078] Fig.18 This is the tumor volume growth curve after AAV-mediated cMSC-driven immune combination factor treatment of mouse xenograft tumors.

[0079] Fig.19 It is the gene circuit platform based on c-MYC identification in Example 8. DETAILED DESCRIPTION

[0080] The technical solution of the present invention is further described below by specific embodiments, which do not limit the protection scope of the present invention. Some non-essential modifications and adjustments made by others based on the concept of the present invention still fall within the protection scope of the present invention.

[0081] Terminology explanation:

[0082] Transcription factor genes refer to genes that encode transcription factor proteins. Transcription factors are an important class of protein molecules that play a key role in regulating gene expression. These proteins can recognize and bind to specific DNA sequences, usually located in the promoter region or enhancer region of the gene, thereby affecting the access of RNA polymerase to the gene template DNA and the transcription efficiency. Through this binding, transcription factors can activate or inhibit the transcription process of specific genes, thereby regulating the synthesis of proteins in cells, affecting cell function, growth, differentiation, and response to environmental signals.

[0083] Transcription factors include universal transcription factors, which are part of the basic transcription machinery and are essential for all gene transcription. For example, universal transcription factors for RNA polymerase II include TFIID, TFIIB, TFIIE, TFIIF and TFIIH. It also includes tissue-specific transcription factors: such transcription factors are usually only expressed in specific cell types or specific developmental stages, and are involved in cell differentiation and tissue specialization. Such as Oct4, Sox2 and Nanog (important in embryonic stem cells), MyoD (involved in muscle cell differentiation), etc. It also includes signal response transcription factors: activated in response to external signals (such as hormones, growth factors), regulating gene expression to cope with environmental changes. For example, NF-κB is involved in inflammatory responses, and STAT family members respond to cytokine signals. It also includes nucleoproteins: such as nucleoprotein 1 and nucleoprotein 2, which contain DNA binding domains and transcriptional activation domains and are involved in processes such as embryonic development, cell proliferation and immune response. It also includes family transcription factors: those transcription factors that are classified into the same family based on their structural and functional characteristics, such as zinc finger protein family, helix-loop-helix (HLH) family, basic helix-loop-helix (bHLH) family (c-MYC, N-MYC), homeodomain family, E2F family (E2F1, E2F2, E2F3), etc. It also includes the basic helix-helix-lysine-threonine (bHLH-LZ) family: this type of transcription factor plays a role in regulating a variety of cellular processes such as cell cycle, differentiation and development.

[0084] As an example, the transcription factor in the present invention can be selected from one or more of c-MYC, N-MYC, L-MYC, E2F1, E2F2, E2F3, CREB, NF-κB, STAT (signal transducers and activators of transcription), AP-1 (activator protein 1), bzip, HMG, etc.

[0085] Tumor immune activation factors refer to biologically active molecules that can promote the immune system to recognize and attack tumor cells. These factors play a key role in regulating immune responses and enhancing anti-tumor immunity. As an exemplary example, the tumor immune activation factors include (1) cytokines: interferon-γ (IFN-γ): enhances the anti-tumor activity of immune cells, promotes M1 macrophage polarization, and enhances the killing power of CD8+ cytotoxic T lymphocytes (CTL); interleukin-2 (IL-2): promotes the proliferation and activation of T cells and natural killer cells (NK cells); IL-12: promotes Th1 immune response and enhances cell-mediated immune response. IL-15: supports the survival and function of NK cells and memory T cells. IL-18: synergizes with IL-12 to enhance Th1 response and IFN-γ production. Tumor necrosis factor-α (TNF-α): has anti-tumor and pro-inflammatory effects and can induce tumor cell apoptosis. IL-7: promotes the development, survival and proliferation of T cells. (2) Co-stimulatory molecules and their agonists: OX40 (CD134) agonists: enhance T cell activity and survival; 4-1BB (CD137) agonists: enhance anti-tumor immunity by providing T cell co-stimulatory signals; CD27 agonists: promote the activation of T cells and NK cells. (3) Checkpoint inhibitors: anti-PD-1 / PD-L1 antibodies: relieve tumor cells from immunosuppression of T cells; anti-CTLA-4 antibodies: such as Ipilimumab, enhance immune response by blocking T cell inhibitory signals. (4) Chemokines: such as CCL5, attract immune cells to the tumor site and promote immune cell infiltration. (5) Colony stimulating factors: such as GM-CSF: promote dendritic cell maturation and antigen presentation, enhance immune response; (6) Immune cell activators: TGF-β antagonists: inhibit immunosuppression in the tumor microenvironment. (7) Oncolytic viruses and immune adjuvants: Oncolytic viruses can directly kill tumor cells and release tumor antigens, thereby activating the immune system; immune adjuvants such as CpG oligonucleotides can enhance antigen presentation and activate innate and adaptive immunity.

[0086] Self-cleaving peptides are peptides that can self-cleave, and are commonly used in multi-protein co-expression strategies to allow one mRNA transcript to generate multiple independent protein products. In some exemplary embodiments, the self-cleaving peptides of the present invention include: T2A (derived from Thosea asigna virus), P2A (derived from poliovirus), E2A (derived from Equine Rhinitis A Virus, equine rhinitis virus A), F2A (derived from Foot-and-MouthDisease Virus, foot-and-mouth disease virus) and one or more thereof.

[0087] Tumors include, but are not limited to, esophageal cancer, gastric cancer, liver cancer (including hepatocellular carcinoma, bile duct cancer), pancreatic cancer, colorectal cancer (including cecal cancer, colon cancer, rectal cancer), gallbladder cancer, islet cell tumor, lung cancer (such as small cell lung cancer, non-small cell lung cancer), pleural mesothelioma, bladder cancer, kidney cancer (such as renal cell carcinoma, renal pelvis cancer), prostate cancer, testicular cancer, ovarian cancer, cervical cancer, endometrial cancer, vaginal cancer, leukemia (acute, chronic), lymphoma (Hodgkin lymphoma, non-Hodgkin lymphoma), multiple myeloma, brain tumor (such as glioma, meningioma, pituitary tumor, acoustic neuroma), spinal cord tumor, thyroid cancer, parathyroid tumor, insulinoma, melanoma, basal cell carcinoma, squamous cell carcinoma, osteosarcoma, Ewing's sarcoma, liposarcoma, leiomyosarcoma, oral cancer, nasopharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, thyroid cancer, breast cancer, eye tumor, heart tumor (such as atrial myxoma).

[0088] Example 1 Gene receptors that sense different expressions of oncogenes in cells

[0089] In this example, we used c-MYC as a representative oncogene and fluorescent protein as a representative target gene, and prepared a gene circuit that can sense different c-MYC expressions, which contains oncogene activating sensors and oncogene inhibitory sensors.

[0090] c-MYC-activator-GFP

[0091] Among them, the oncogene-activating receptor contains an oncogene-activating promoter (in this case, the oncogene is c-MYC, and the oncogene-activating promoter is referred to as "c-MYC-activator"), and the target gene is represented by green fluorescent protein GFP, and the oncogene-activating promoter drives the expression of the target gene GFP.

[0092] c-MYC-activator Figure 1a, composed of a DNA sequence (c-MYC-BS) specifically bound by an oncogene protein (c-MYC) and a transcriptionally activated promoter core (core promoter) arranged in cis. We generated a c-MYC-activator-based specific promoter (c-MYC-activator) from known c-MYC binding motifs and encoded multiple (such as 2, 3, 4, 5, 6, 7, 8, 9, 10) binding motifs (c-MYC-BS) in tandem upstream of the transcriptionally activated promoter core (core promoter). In our design, each basic c-MYC motif, in addition to the consensus E-box, also contains a characteristic DNA sequence with high affinity to WDR5, which effectively recruits c-MYC to enhance the activity of the core promoter (core promoter), thereby driving the expression of the downstream target gene green fluorescent protein (GFP) to test their specificity and activity in different c-MYC expressing cells.

[0093] We used lentivirus to stably express tetracycline-induced c-MYC expression in HEK-293t cells (293t-MYC), and added 1 μg / ml tetracycline to 293t-MYC cells to construct c-MYC high-expressing cells (high-MYC). At the same time, HEK-293t cells were transfected with c-MYC siRNA (si-MYC) to construct c-MYC low-expressing cells (low-MYC). 48 hours after the c-MYC-activator-GFP vector was transfected into c-MYC high-expressing cells and c-MYC low-expressing cells, 10 cells were collected in each group. 4 The mean fluorescence intensity (MFI) of GFP in each group of cells was analyzed by flow cytometry, which is the relative expression level of GFP. All results are shown in Figure 1 In b, c-MYC-activator is more active in cells with high c-MYC expression than in cells with low c-MYC expression.

[0094] We seeded 293t-MYC cells in 24-well cell culture plates for 10 5 After 12 hours, 1 μg / ml si-MYC, 0 μg / ml, 0.25 μg / ml, 0.5 μg / ml, and 1 μg / ml tetracycline were added to each group of cells, respectively. After 12 hours, 0.4 ng of c-MYC-activator-GFP vector was transfected into each group of cells. After 48 hours, representative GFP fluorescence images of each group of cells were taken under an inverted microscope. 10 4 The proportion of GFP-expressing cells in each group was analyzed by flow cytometry. Figure 1 c). The results showed that as the expression of c-MYC in cells increased, the transcriptional activity of c-MYC-activator became stronger and stronger, so that the expression of GFP increased, that is, the proportion of GFP-positive cells and the mean fluorescence intensity (MFI) values ​​increased.

[0095] SEQ ID NO:1c-MYC-activator:

[0096] TCCGCCCGGTCACGTGACGCGACAGTCCGCCCGGTCACGTGACGCGACAGTCCGCCCGGTCACGTGACGCGACTGGTC

[0097] CGCCCGGTCACGTGACGCGACCGTCCGCCCGGTCACGTGACGCGACCGGTCCGCCCGGTCACGTGACGCGACCGTCCG

[0098] CCCGGTCACGTGACGCGACGTGTCCGCCCGGTCACGTGACGCGCCAGACGCTAGCGGGGGGCTATAAAAgggggtgggggcg

[0099] ttcgtcctcactctagatctgc

[0100] SEQ ID NO: 2si-MYC positive strand;

[0101] AACAGAAAUGUCCUGAGCAAUTT

[0102] SEQ ID NO:3si-MYC antisense strand

[0103] AUUGCUCAGGACAUUUCUGUUTT

[0104] c-MYC-repressor-RFP

[0105] Among them, the oncogene inhibitory receptor contains an oncogene inhibitory promoter (in this case, the oncogene is represented by c-MYC, and the target gene is represented by red fluorescent protein RFP, and the oncogene inhibitory promoter is referred to as "c-MYC-repressor"), which inhibits the expression of the target gene.

[0106] c-MYC-repressor Figure 2a, which consists of a DNA sequence (c-MYC-BS) that is specifically bound by an oncogene protein and a promoter core (represented by INK4B-core in this case) that is transcriptionally repressed. c-MYC-BS effectively recruits c-MYC to inhibit the activity of the core promoter (INK4B-core), thereby inhibiting the expression of the downstream target gene red fluorescent protein (RFP).

[0107] We used lentivirus to stably express tetracycline-induced c-MYC expression in HEK-293t cells (293t-MYC), and added 1 μg / ml tetracycline to 293t-MYC cells to construct c-MYC high-expressing cells (high-MYC). At the same time, HEK-293t cells were transfected with c-MYC siRNA (si-MYC) to construct c-MYC low-expressing cells (low-MYC). 48 hours after the c-MYC-repressor-RFP vector was transfected into c-MYC high-expressing cells and c-MYC low-expressing cells, 10 cells were collected in each group. 4 The mean fluorescence intensity (MFI) of RFP in each group of cells was analyzed by flow cytometry, which is the relative expression level of RFP. All results are shown in Figure 2 In b, the relative expression of 293t-MYC GFP incubated with 1 μg / ml tetracycline was high, c-MYC was highly expressed (high-myc), and 293t-MYC transfected with c-MYC siRNA was lowly expressed (low-MYC). 293t-MYC cells were grown in 24-well cell culture plates for 10 5 After 12 hours, 1ug / ml tetracycline, 0μg / ml, 0.25μg / ml, 0.5μg / ml, and 1μg / ml si-MYC were added to each group of cells. After 12 hours, 0.4ng of c-MYC-repressor-RFP vector was transfected into each group of cells. After 48 hours, representative RFP fluorescence images of each group of cells were taken under an inverted microscope. 10 4 The proportion of RFP-expressing cells in each group was analyzed by flow cytometry. Figure 2 c). As the expression of c-MYC in cells increases, the transcriptional activity of c-MYC-repressor becomes weaker and weaker, so that the expression of RFP becomes lower and lower, that is, the proportion of RFP-positive cells and the mean fluorescence intensity (MFI) values ​​become smaller and smaller. The promoter driving the expression of the INK4B gene showed a 2.7-fold inhibitory effect in cells with high and low c-MYC expression.

[0108] SEQ ID NO:4c-MYC-repressor:

[0109] CCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCTTGGC

[0110] CCCCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCTTG

[0111] GCCCCCCGGGCCTGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCT

[0112] TGGCCCCCCGGGCCTGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCC

[0113] CTTGGCCCAGCTGAAAACGGAATTCTTTGCCGGCTGGCTCCCCACTCT

[0114] Example 2 Transcriptional activity of c-MYC-activator and c-MYC-repressor at different c-MYC levels

[0115] We established that the transcriptional activity of c-MYC-activator (same as Example 1) gradually increases with the increase of c-MYC expression ( Figure 3 a), while the transcriptional activity of c-MYC-repressor (same as Example 1) was gradually inhibited as the c-MYC level increased ( Figure 3 b).

[0116] 293t-MYC cells were grown in 24-well cell culture plates for 10 5 After 12 hours, 1 μg / ml si-MYC, 0 μg / ml, 0.25 μg / ml, 0.5 μg / ml, and 1 μg / ml tetracycline were added to each group of cells. After 12 hours, 0.4 ng of c-MYC-activator-GFP vector was transfected into each group of cells. After 48 hours, 10 4 The proportion of GFP-expressing cells in each group was analyzed by flow cytometry. Figure 3a), accordingly, the transcription level of c-MYC mRNA in each group of cells was detected by qPCR experiment. As the expression of c-MYC in the cells increased, the transcription activity of c-MYC-activator became stronger and stronger, so that the expression of GFP increased, that is, the proportion of GFP-positive cells and the mean fluorescence intensity (MFI) values ​​increased ( Figure 3 a).

[0117] 293t-MYC cells were grown in 24-well cell culture plates for 10 5 After 12 hours, 1ug / ml tetracycline, 0μg / ml, 0.25μg / ml, 0.5μg / ml, and 1μg / ml si-MYC were added to each group of cells. After 12 hours, 0.4ng of c-MYC-repressor-RFP vector was transfected into each group of cells. After 48 hours, 10 4 The proportion of RFP-expressing cells in each group was analyzed by flow cytometry. Figure 3 b), accordingly, the transcription level of c-MYC mRNA in each group of cells was detected by qPCR experiment. As the expression of c-MYC in cells increased, the transcription activity of c-MYC-repressor became weaker and weaker, so that the expression of mcherry (RFP) became lower and lower, that is, the proportion of mcherry (RFP) positive cells and the mean fluorescence intensity (MFI) values ​​became smaller and smaller ( Figure 3 b)

[0118] Example 3 Uniquely designed target gene inhibition system - self-cleavage system and inhibition effects of different inhibitory elements

[0119] We hypothesized that the inhibitory element expressed by the oncogene inhibitory sensor c-MYC-repressor could be used to inhibit the target gene driven by c-MYC-activator, thereby offsetting the unnecessary expression (false positive) of the target gene by the oncogene activating promoter c-MYC-activator in cells with low c-MYC expression. In order to enable the inhibitory element expressed by the oncogene inhibitory sensor c-MYC-repressor to effectively degrade the target mRNA of the target gene expressed by the oncogene activating promoter c-MYC-activator without producing off-target effects, we designed a unique inhibitory element based on artificial RNA (aRNA) and its unique matching binding site (aRNA-BS), which together constitute a self-cleavage system. At the gene sequence level or in the gene circuit, the two are located in different sensors, where aRNA is located in the oncogene inhibitory sensor, corresponding to the inhibitory element of the target gene of the oncogene inhibitory sensor, and aRNA-BS is located in the oncogene activating sensor, corresponding to the binding sequence of the inhibitory element of the target gene.

[0120] Structure of the self-cleavage system aRNA / aRNA-BS

[0121] Figure 4 Figure 2 is a state diagram of the post-transcriptional binding between aRNA and aRNA-BS. The aRNA-BS is designed to consist of a 5' hammerhead ribozyme and a 3' miRNA binding site. Multiple (for example, 10) aRNA-BSs are encoded in tandem in the 3' cassette encoding the mRNA encoding the target gene (GFP).

[0122] The aRNA is designed to consist of the 3' hammerhead ribozyme and the 5' sequence of miRNA, and is expressed through an optimized pri-miRNA backbone to improve the production efficiency of aRNA. The structural framework of the aRNA precursor (pri-miRNA) is shown in Figure 5a, a structure in which the expression of miRNA precursor is mediated by 3'tailed mitron. The precursor structure of aRNA mainly includes (displayed from 5' to 3'): guide strand, loop sequence (TTCAAGAGA), passenger strand and ribozyme tract. The precursor structure of aRNA starts from 5'splice donor motif and ends with 3'splice acceptor motif. The guide strand and the transition strand (21bp in length) form a hairpin structure through the Watson-Crick base pair principle, and mismatches are purposefully introduced at the base of the stem to promote the selection of the guide strand by the RNA-induced silencing complex (RISC). For a specific aRNA structure and sequence, see Figure 5 b.

[0123] The workflow of the self-cleavage system aRNA / aRNA-BS in cells is shown in Figure 5 c. After the mature aRNA is successfully transcribed, it will recruit the Ago protein in the cell to bind to it. The Ago protein is a protein that plays a core role in the RNA-induced silencing complex (RISC). It can bind to some small single-stranded RNAs (guide RNAs) or small single-stranded DNAs (guide DNAs) to cause the cutting of the target RNA sequence. When the transcribed aRNA and aRNA-BS are complementary, the ribozymes designed on the aRNA / aRNA-BS will be activated and degraded. At this time, the miRNA designed on the aRNA can be separated from the ribozyme structure from the original aRNA design, so that the mRNA molecule where the miRNA binding sequence is located can be further hydrolyzed. In summary, after the designed aRNA binds to the aRNA-BS, it will activate and induce the aRNA itself to degrade the target gene mRNA where the aRNA-BS is located three times, thereby degrading the target gene mRNA and achieving the purpose of efficiently inhibiting the expression of the target gene.

[0124] Verification of the cleavage efficiency of different inhibitory elements

[0125] We systematically validated and optimized various aspects of aRNA / aRNA-BS and described how the sequence and composition of aRNA / aRNA-BS determine the efficiency of this system ( Figure 6 ).

[0126] In 293t cells, the gene sequence of c-MYC-activator-GFP was inserted into the pCAG-T7pol vector (Addgene no.59926), and the gene sequence of c-MYC-repressor-RFP was inserted into the pCAG-T7pol vector (Addgene no.59926). Vectors containing different inhibitory elements were transfected respectively. The inhibitory elements and vector structures transfected in each group of cells are briefly described as follows. For details, see Figure 6 (Left) as shown (arranged from top to bottom):

[0127] The original GFP coding sequence was expressed using the CMV promoter;

[0128] The original miRNA binding sequence (miR-BS) was added to the 3′ end of the GFP coding sequence when expressed using the CMV promoter;

[0129] The miRNA binding sequence (miR-BS+ribozyme) modified with ribozyme was added to the 3' end of the GFP coding sequence by expressing it with CMV promoter;

[0130] The original miRNA binding sequence (miR-BS) was added to the 3' end of the GFP coding sequence using the CMV promoter to express the original miRNA, and the original miRNA was expressed using the U6 promoter;

[0131] The miRNA binding sequence modified with ribozyme (miR-BS+ribozyme) was added to the 3' end of the GFP coding sequence using the CMV promoter to express the original miRNA using the U6 promoter;

[0132] The original miRNA binding sequence (miR-BS) was added to the 3' end of the GFP coding sequence using the CMV promoter to express, and the miRNA sequence modified with a mutated non-functional ribozyme (original miRNA+mutationalribozyme) was expressed using the U6 promoter;

[0133] The miRNA binding sequence modified with ribozyme (miR-BS+ribozyme) was added to the 3' end of the GFP coding sequence by using CMV promoter to express, and the miRNA sequence modified with mutated and non-functional ribozyme (originalmiRNA+mutational ribozyme) was expressed by U6 promoter;

[0134] The miRNA binding sequence modified with ribozyme (miR-BS+ribozyme) was added to the 3' end of the GFP coding sequence by expressing it with CMV promoter, and the miRNA sequence modified with ribozyme (original miRNA+ribozyme) was expressed by U6 promoter;

[0135] The original miRNA binding sequence (miR-BS) was added to the 3' end of the GFP coding sequence when expressed with the CMV promoter, and the miRNA sequence modified with ribozyme (original miRNA+ribozyme) was expressed with the U6 promoter;

[0136] The miRNA binding sequence (miR-BS+mutational ribozyme) modified with the mutated non-functional ribozyme was added to the 3' end of the GFP coding sequence using the CMV promoter, and the miRNA sequence (original miRNA+ribozyme) modified with the ribozyme was expressed using the U6 promoter.

[0137] 48 hours after transfection, 10 cells were collected from each group. 4 The mean fluorescence intensity (MFI) of GFP-expressing cells in each group of cells was analyzed by flow cytometry, and the inhibition efficiency of various construction strategies was evaluated by the size of the MFI in each group of cells.

[0138] By comparing the above verification and optimization design, it was found that when the miRNA binding sequence modified with ribozyme (miR-BS+ribozyme) was added to the 3' end of the GFP coding sequence by using the CMV promoter to express the miRNA sequence modified with ribozyme (original miRNA+ribozyme) and the miRNA sequence modified with ribozyme (original miRNA+ribozyme) was expressed by the U6 promoter, the combination of the two had the highest inhibition efficiency on GFP coding ( Figure 6 Therefore, we selected the original miRNA+ribozyme sequence as aRNA (artificial RNA), corresponding to the inhibitory element that inhibits the expression of the target gene, and the miRNA-BS+ribozyme sequence as the aRNA-binding site (aRNA-BS), corresponding to the binding sequence of the inhibitory element in the target gene.

[0139] For detailed experimental results, see Figure 6(Right) In terms of the inhibition efficiency of the target gene GFP, aRNA showed a better inhibitory effect (~96%) than the original miRNA (~72%). In addition, the increase in the transcriptional activity of the promoter driving the transcription of aRNAs has a better inhibitory effect on the expression of the target gene GFP. More importantly, the expression efficiency of the target gene (GOI) mRNA recombined with aRNA-BS only decreased negligibly. And aRNA / aRNA-BS has almost no off-target performance in different cells.

[0140] SEQ ID NO:5 aRNA:

[0141] GTAAGATGCTTCTTAACCTTGCTTCAAGAGAGCAAGGTTAAGAAGCATCTGTCGGGGCTCTGATGAGGCCGAAAGGCC

[0142] GAAACCAAGC

[0143] SEQ ID NO:6aRNA-BS:

[0144] CTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATGGCTTTTTAACCTTGC

[0145] Example 4 Gene circuit containing a self-cleavage system

[0146] Next, aRNA / aRNA-BS were connected to c-MYC-activator and c-MYC-repressor, respectively, to construct a gene circuit (c-MYC sensing circuit, cMSC) based on c-MYC to distinguish the physiological expression and pathological expression of c-MYC gene ( Figure 7 a). In the cMSC containing the self-cleaving system, in which the oncogene activating receptor, we use c-MYC-activator to drive the expression of the target gene GFP, and the GFP expression coding box is tandem-designed with the aRNA-BS in the self-cleaving system, and in the oncogene inhibitory receptor, MYC-repressor is used to drive the expression of aRNA matching aRNA-BS to specifically cut the mRNA of GFP. In addition, BFP expression is used to mark cells transfected with the cMSC vector.

[0147] We then determined the efficiency of the self-cleaving system cMSC in cells with different c-MYC expressions. We used lentivirus to stably express tetracycline-induced c-MYC expression in HEK-293t cells (293t-MYC), and added 1 μg / ml tetracycline in 293t-MYC cells to construct c-MYC high-expressing cells (high-MYC). cMSC-GFP vectors were transfected in c-MYC high-expressing cells, c-MYC low-expressing cells and wild-type 293t cells, and 10 cells were collected from each group after 48 hours. 4 The mean fluorescence intensity (MFI) of GFP in each group of cells was analyzed by flow cytometry. It was found that the GFP expression of cells with low c-MYC expression and bare HEK-293t cells was very low, while the GFP expression of cells with high c-MYC expression was slightly higher (about 27 times) than that of bare HEK-293t cells ( Figure 8 a).

[0148] To further confirm these results, we set different expression levels of c-MYC in 293t cells to evaluate the ability of cMSCs to sense endogenous c-MYC. 293t-MYC cells were seeded in 24-well cell culture plates for 10 5 After 12 hours, 1 μg / ml si-MYC, 0 μg / ml, 0.25 μg / ml, 0.5 μg / ml, and 1 μg / ml tetracycline were added to each group of cells. After 12 hours, 0.4 ng of cMSC-GFP vector was transfected into each group of cells. After 48 hours, the mean fluorescence intensity (MFI) of GFP in each group of cells was analyzed by flow cytometry, which is the relative expression level of GFP. All results are shown in Figure 7 As expected, GFP expression increased with the increase in c-MYC expression ( Figure 7 c).

[0149] Next, we seeded 293t-MYC cells in 24-well cell culture plates for 10 5 After 12 hours, 1 μg / ml si-MYC, 0 μg / ml, 0.25 μg / ml, 0.5 μg / ml, and 1 μg / ml tetracycline were added to each group of cells. After 12 hours, 0.4 ng of c-MYC-activator-GFP vector was transfected into each group of cells. After 48 hours, representative GFP fluorescence images of each group of cells were taken under an inverted microscope ( Figure 8 b), 10 cells were collected from each group of cells. 4 The proportion of GFP-expressing cells in each group was analyzed by flow cytometry. Figure 8b). The results showed that as the expression of c-MYC in cells increased, the activity of cMSC in driving the expression of downstream target genes became stronger, so that the expression of GFP increased, that is, the proportion of GFP-positive cells and the mean fluorescence intensity (MFI) values ​​increased. In addition, we found that when c-MYC was expressed at a low level in cells, cMSC would not drive the expression of target genes.

[0150] In addition, we verified the effectiveness of cMSC in in vitro cell lines by collecting the same number of cells from different types of cells in vitro. The specific experiment was to transfect the expression vector of cMSC-GFP in normal bladder mucosal epithelial cell line (SVHUC1), bladder cancer cell line (T24, UMUC3) and cervical cancer cell line (HeLa) cells, and collect 10 cells from each group of cells after 48 hours. 4 The proportion of GFP-expressing cells in each group of cells was analyzed by flow cytometry. The results showed that compared with normal cells (SVHUC1), cancer cell lines T24 (23.6 times), UMUC3 (20.5 times) and HeLa (24.2 times) showed relatively higher GFP expression ( Figure 8 c). In summary, aRNA / aRNA-BS was constructed and used to solve the problem of high false-positive transcriptional activity.

[0151] SEQ ID NO: 7 cMSC-GFP containing a self-cleavage system:

[0152] CCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCTTGGC

[0153] CCCCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCTTG

[0154] GCCCCCCGGGCCTGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCT

[0155] TGGCCCCCCGGGCCTGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCC

[0156] CTTGGCCCAGCTGAAAACGGAATTCTTTGCCGGCTGGCTCCCCACTCTGTAAGATGCTTCTTAACCTTGCTTCAAGAGA

[0157] GCAAGGTTAAGAAGCATCTGTCGGGGCTCTGATGAGGCCGAAAGGCCGAAACCAAGGTAAGATGCTTCTTAACCTTGC

[0158] TTCAAGAGAGCAAGGTTAAGAAGCATCTGTCGGGGCTCTGATGAGGCCGAAAGGCCGAAACCAAGTCCGCCCGGTCA

[0159] CGTGACGCGACAGTCCGCCCGGTCACGTGACGCGACAGTCCGCCCGGTCACGTGACGCGACTGGTCCGCCCGGTCACG

[0160] TGACGCGACCGTCCGCCCGGTCACGTGACGCGACCGGTCCGCCCGGTCACGTGACGCGACCGTCCGCCCGGTCACGTG

[0161] ACGCGACGTGTCCGCCCGGTCACGTGACGCGCCAGACGCTAGCGGGGGGCTATAAAAgggggtgggggcgttcgtcctcactctagatctg

[0162] cATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCA

[0163] CAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGG

[0164] CAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCAC

[0165] ATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC

[0166] GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGA

[0167] CTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGA

[0168] CAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACC

[0169] ACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCC

[0170] TGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCA

[0171] TGGACGAGCTGTACAAGCTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGT

[0172] CAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAA

[0173] GGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAAC

[0174] CTTGCCTTGGTCAGCCCCTTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGAT

[0175] GAGGCCGAAAGGCCGAAACAGATGCTTTTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGA

[0176] TGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTC

[0177] AGCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCGAAAG

[0178] GCCGAAACAGATGCTTCTTAACCTTGC

[0179] Example 5 GOI expression amplification system (GEAS) containing different strong transcription activators and verification of its amplification efficiency

[0180] In order to amplify the expression of target genes driven by cMSCs in c-MYC high expression, we designed a feed-forward loop - the target gene expression amplification system (GEAS) to amplify the expression of the target gene (GOI). The target gene expression amplification system contains the gene sequence of a strong transcription activator and its binding site. The binding site of the strong transcription activator is located at the 5' end of the activating promoter of the oncogene.

[0181] We compared the amplification efficiency of different strong transcriptional activators, including (1) a transcription factor synthesized by fusion of yeast GAL4 and VP64 (GAL4-VP64), (2) the original transcriptional activator KLF6, and (3) our reconstructed transcriptional activator KLFa based on partial domains of KLF6 and VP64, and their transcriptional activation in HEK-293t cells.

[0182] Experimental steps: GAL4-VP64, KLF6 and KLFa were expressed by CAG promoter and inserted into pCAG-T7pol vector (Addgene no.59926). GFP expression was driven by miniCMV promoter and inserted into pCAG-T7pol vector (Addgene no.59926). We seeded 10 5 HEK-293t cells were transfected with 0.2 ng of the above CAG-GAL4-VP64, CAG-KLF6 and CAG-KLFa respectively and 0.2 ng of miniCMV-GFP (a total of 0.4 ng of plasmid). 10 cells were collected from each group after 48 hours. 4 The average fluorescence intensity of GFP in each group of cells was analyzed by flow cytometry.

[0183] The experimental results showed that KLFa had the strongest activation effect on the promoter (~222 times), followed by KLF6 (~179 times), while GAL4-VP64 had the weakest activation effect (~162 times) ( Fig. 9 ).

[0184] Next, we constructed an expression amplification system based on a strong transcriptional activator ( Fig.10 a), the amplification system contains the binding site (BS) of a strong transcription activator, the hydrolyzed polypeptide sequence at the 3' end of the target gene (GFP) coding sequence (in this case, the T2A coding sequence), and the strong transcription activator expression cassette at the 3' end, encoding GAL4-VP64, KLF6 and KLFa respectively. These expression sequences are driven by a tetracycline-inducible promoter, in which the six binding sites of GAL4-VP64, KLF6 and KLFa are tandemly encoded in the 5' tetracycline-inducible promoter ( Fig.10 a). We seeded 10 5 HEK-293t cells were transfected with 0.4 ng of the above plasmids in each group of cells 12 hours later. 10 cells were collected from each group of cells 48 hours later. 4 The average fluorescence intensity of GFP in each group of cells was analyzed by flow cytometry. As expected, these transcription activator-based expression amplification systems all enhanced GFP expression, among which the expression amplification system based on the strong transcription activator KLFa had the highest activation efficiency ( Fig.10 b), Two other strong transcriptional activators also have high activation level efficiencies.

[0185] SEQ ID NO:8 KLFa:

[0186] ATGGACGTTCTGCCCATGTGCTCTATCTTTCAGGAACTTCAGATTGTGCACGAGACAGGATACTTTTCAGCTCTCCCCTC

[0187] TCTGGAGGAGTATTGGCAACAAACATGCCTGGAACTGGAGCGCTACTTGCAGTCCGAGCCTTGTTACGTCTCTGCTAGT

[0188] GAAATCAAGTTCGACTCACAGGAGGACCTCTGGACCAAGATTATTCTGGCGCGCGAAAAGAAGGAGGAGTCCGAACTG

[0189] AAGATCTCTTCTAGCCCGCCGGAGGATACCCTGATCAGCCCTAGCTTCTGCTACAATCTCGAGACCAACAGCCTCAATTC

[0190] TGATGTTAGCAGTGAATCCAGTGACTCTTCCGAGGAGCTGTCCCCAACCGCTAAATTCACATCCGATCCTATCGGGGAAG

[0191] TTCTTGTGAGCTCCGGTAAGCTGAGTAGCTCCGTGACCTCTACACCCCCTAGCAGCCCTGAGTTGAGCAGGGAACCGAG

[0192] CCAGCTTTGGGGCTGTGTCCCAGGAGAGTTGCCTTCCCCTGGTAAGGTCAGATCAGGCACATCCGGTAAACCTGGGGAT

[0193] AAAGGCAATGGAGACGCTTCACCTGACGGGAGAAGAAGGGTGCACAGATGTCACTTCAACGGCTGCCGCAAAGTTTAT

[0194] ACCAAATCCTCCCATCTCAAAGCACACCAGCGCACACACACGGGGGAGAAACCCTATAGATGTTCCTGGGAGGGATGC

[0195] GAGTGGCGATTTGCAAGGAGCGATGAGCTGACGAGGCATTTTCGCAAACACACCGGGGCTAAACCTTTCAAATGCTCC

[0196] CACTGCGACCGCTGCTTTTCCAGGTCCGATCACTTGGCTCTGCACATGAAGCGGCATCTCGAGGCCAGCGGTTCCGGAC

[0197] GGGCTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGGT

[0198] TCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCCTTGATGATTTCGACCTGGACATGCTGATTAA

[0199] CTCTAGA

[0200] SEQ ID NO:9GAL4-VP64:

[0201] ATGAAGCTACTGTCTTCTATCGAACAAGCATGCGATATTTGCCGACTTAAAAAGCTCAAGTGCTCCAAAGAAAAACCGA

[0202] AGTGCGCCAAGTGTCTGAAGAACAACTGGGAGTGTCGCTACTCTCCCAAAACCAAAAGGTCTCCGCTGACTAGGGCAC

[0203] ATCTGACAGAAGTGGAATCAAGGCTAGAAAGACTGGAACAGCTATTTCTACTGATTTTTCCTCGAGAAGACCTTGACAT

[0204] GATTTTGAAAATGGATTCTTTACAGGATATAAAAGCATTGTTAACAGGATTATTTGTACAAGATAATGTGAATAAAGATGC

[0205] CGTCACAGATAGATTGGCTTCAGTGGAGACTGATATGCCTCTAACATTGAGACAGCATAGAATAAGTGCGACATCATCAT

[0206] CGGAAGAGAGTAGTAACAAAGGTCAAAGACAGTTGACTGTATCGGGCGGTAGTGGAGGAAGCGGGGGGAGCGGAGG

[0207] GAGTGGTGGATCCGGCGGCTCCGAGGCCAGCGGTTCCGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGCTG

[0208] GGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGG

[0209] CAGTGACGCCCTTGATGATTTCGACCTGGACATGCTGATTAACTCTAGA

[0210] SEQ ID NO:10KLF6:

[0211] ATGGACGTTCTGCCCATGTGCTCTATCTTTCAGGAACTTCAGATTGTGCACGAGACAGGATACTTTTCAGCTCTCCCCTC

[0212] TCTGGAGGAGTATTGGCAACAAACATGCCTGGAACTGGAGCGCTACTTGCAGTCCGAGCCTTGTTACGTCTCTGCTAGT

[0213] GAAATCAAGTTCGACTCACAGGAGGACCTCTGGACCAAGATTATTCTGGCGCGCGAAAAGAAGGAGGAGTCCGAACTG

[0214] AAGATCTCTTCTAGCCCGCCGGAGGATACCCTGATCAGCCCTAGCTTCTGCTACAATCTCGAGACCAACAGCCTCAATTC

[0215] TGATGTTAGCAGTGAATCCAGTGACTCTTCCGAGGAGCTGTCCCCAACCGCTAAATTCACATCCGATCCTATCGGGGAAG

[0216] TTCTTGTGAGCTCCGGTAAGCTGAGTAGCTCCGTGACCTCTACACCCCCTAGCAGCCCTGAGTTGAGCAGGGAACCGAG

[0217] CCAGCTTTGGGGCTGTGTCCCAGGAGAGTTGCCTTCCCCTGGTAAGGTCAGATCAGGCACATCCGGTAAACCTGGGGAT

[0218] AAAGGCAATGGAGACGCTTCACCTGACGGGAGAAGAAGGGTGCACAGATGTCACTTCAACGGCTGCCGCAAAGTTTAT

[0219] ACCAAATCCTCCCATCTCAAAGCACACCAGCGCACACACACGGGGGAGAAACCCTATAGATGTTCCTGGGAGGGATGC

[0220] GAGTGGCGATTTGCAAGGAGCGATGAGCTGACGAGGCATTTTCGCAAACACACCGGGGCTAAACCTTTCAAATGCTCC

[0221] CACTGCGACCGCTGCTTTTCCAGGTCCGATCACTTGGCTCTGCACATGAAGCGGCATCTC

[0222] Example 6 Gene circuit containing both self-cleavage system and expression amplification system

[0223] In order to optimize cMSCs to amplify the expression of target genes, we redesigned cMSCs containing a self-cleavage system using an expression amplification system based on the strong transcriptional activator KLFa, and obtained a gene circuit containing both a self-cleavage system and an expression amplification system ( Fig.11 ). For the oncogene-activating receptor, it contains an oncogene-activating promoter (c-MYC-activator), a target gene (GFP), a self-hydrolyzed polypeptide (P2A), a strong transcription activator (KLFa), and an aRNA-BS sequence in a self-cleaving system arranged in cis ( Fig.11Specifically, multiple KLFa binding sites are encoded at the 5' end of the c-MYC-activator sequence (target gene activation promoter), and the sequence driven by the activation promoter is composed of the following components (arranged in order from the 5' end to the 3' end): the CDS sequence encoding the target gene (GFP), the T2A coding sequence (hydrolysis polypeptide), the CDS sequence encoding KLFa (expression amplification system) and the aRNA-BS (self-cleavage element) sequence are arranged in cis.

[0224] For the oncogene inhibitory receptor, it contains an oncogene activating promoter (c-MYC-activator) and a cis-arranged aRNA sequence in a self-cleaving system ( Fig.11 superior).

[0225] We seeded 10 cells in 24-well cell culture plates. 5 HEK-293t cells were transfected with 0.4 ng of optimized cMSC vector plasmid in each group of cells 12 hours later. 10 cells were collected in each group of cells 48 hours later. 4 cells, and the proportion of BFP-positive cells in each group of cells was analyzed by flow cytometry. These were cells that had been transfected with the constructed vector. Then, in the BFP-positive cells, the average fluorescence intensity of GFP was analyzed by flow cytometry. The results showed that in HEK-293t cells with low c-MYC expression and naked HEK-293t cells, there was almost no GFP expression in the transfected optimized cMSCs, while there was obvious GFP expression in cells with high c-MYC expression. This shows that the optimized cMSCs have a good inhibitory effect in both 293t cells with low c-MYC expression and wild-type 293t cells. This shows that the cMSCs optimized by the target gene expression amplification system based on the strong transcriptional activator KLFa have a stronger activation effect under high c-MYC expression ( Fig.12 a). In addition, compared with cMSCs containing only the self-cleavage system, cMSCs containing both the self-cleavage system and the expression amplification system showed higher sensitivity and transcriptional activation efficiency at different c-MYC expression levels ( Fig.12 b).

[0226] SEQ ID NO: 11 cMSC-GFP containing both a self-cleavage system and an expression amplification system:

[0227] CCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCTTGGC

[0228] CCCCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCTTG

[0229] GCCCCCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCCCT

[0230] TGGCCCCCCGGGCCTGGCCTCCCGGCGATCACAGCGGACAGGGGGCGGAGCCTAAGGGGGTGGGGAGACGCCGGCCC

[0231] CTTGGCCCAGCTGAAAACGGAATTCTTTGCCGGCTGGCTCCCCACTCTGTAAGATGCTTCTTAACCTTGCTTCAAGAGA

[0232] GCAAGGTTAAGAAGCATCTGTCGGGGCTCTGATGAGGCCGAAAGGCCGAAACCAAGTGAGCGGCCGCAAGGATCTGC

[0233] GATCGCTCCGGTGCCCGTCAGTCGGAGTACTGTCCTCCGAGCGGAGTACTGTCCTCCGACTCGAGCGGAGTACTGTCCT

[0234] CCGATCGGAGTACTGTCCTCCGCGAATTCCGGAGTACTGTCCTCCGTCCGCCCGGTCACGTGACGCGACAGTCCGCCCG

[0235] GTCACGTGACGCGACAGTCCGCCCGGTCACGTGACGCGACTGGTCCGCCCGGTCACGTGACGCGACCGTCCGCCCGGT

[0236] CACGTGACGCGACCGGTCCGCCCGGTCACGTGACGCGACCGTCCGCCCGGTCACGTGACGCGACGTGTCCGCCCGGTC

[0237] ACGTGACGCGCCAGACGCTAGCGGGGGGCTATAAAAgggggtgggggcgttcgtcctcactctagatctgcATGGTGAGCAAGGGCGAGGA

[0238] GCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGA

[0239] GGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCC

[0240] CACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTC

[0241] AAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCC

[0242] GAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACAT

[0243] CCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAA

[0244] GGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCAT

[0245] CGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGA

[0246] AGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGAGG

[0247] GCAGAGGCAGTCTGCTGACATGCGGTGACGTGGAAGAGAATCCCGGCCCTATGGACGTTCTGCCCATGTGCTCTATCTT

[0248] TCAGGAACTTCAGATTGTGCACGAGACAGGATACTTTTCAGCTCTCCCCTCTCTGGAGGAGTATTGGCAACAAACATGC

[0249] CTGGAACTGGAGCGCTACTTGCAGTCCGAGCCTTGTTACGTCTCTGCTAGTGAAATCAAGTTCGACTCACAGGAGGACC

[0250] TCTGGACCAAGATTATTCTGGCGCGCGAAAAGAAGGAGGAGTCCGAACTGAAGATCTCTTCTAGCCCGCCGGAGGATA

[0251] CCCTGATCAGCCCTAGCTTCTGCTACAATCTCGAGACCAACAGCCTCAATTCTGATGTTAGCAGTGAATCCAGTGACTCT

[0252] TCCGAGGAGCTGTCCCCAACCGCTAAATTCACATCCGATCCTATCGGGGAAGTTCTTGTGAGCTCCGGTAAGCTGAGTA

[0253] GCTCCGTGACCTCTACACCCCCTAGCAGCCCTGAGTTGAGCAGGGAACCGAGCCAGCTTTGGGGCTGTGTCCCAGGAG

[0254] AGTTGCCTTCCCCTGGTAAGGTCAGATCAGGCACATCCGGTAAACCTGGGGATAAAGGCAATGGAGACGCTTCACCTGA

[0255] CGGGAGAAGAAGGGTGCACAGATGTCACTTCAACGGCTGCCGCAAAGTTTATACCAAATCCTCCCATCTCAAAGCACA

[0256] CCAGCGCACACACACGGGGGAGAAACCCTATAGATGTTCCTGGGAGGGATGCGAGTGGCGATTTGCAAGGAGCGATGA

[0257] GCTGACGAGGCATTTTCGCAAACACACCGGGGCTAAACCTTTCAAATGCTCCCACTGCGACCGCTGCTTTTCCAGGTCC

[0258] GATCACTTGGCTCTGCACATGAAGCGGCATCTCGAGGCCAGCGGTTCCGGACGGGCTGACGCATTGGACGATTTTGATC

[0259] TGGATATGCTGGGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTC

[0260] GACATGCTCGGCAGTGACGCCCTTGATGATTTCGACCTGGACATGCTGATTAACTCTAGACTTGGTCAGCCCCCTGATGA

[0261] GGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATG

[0262] CTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAG

[0263] CCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAAGGC

[0264] CGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTT

[0265] GCCTTGGTCAGCCCCTTGATGAGGCCGAAAGGCCGAAACAGATGCTTCTTAACCTTGCCTTGGTCAGCCCCCTGATGAG

[0266] GCCGAAAGGCCGAAACAGATGGCTTTTTAACCTTGC

[0267] Example 7 Activation efficiency of gene circuits containing both self-cleavage system and expression amplification system under different environments

[0268] (1) In vitro cell lines

[0269] We further determined the efficiency of the gene circuit (cMSC) containing both the self-cleavage system and the expression amplification system in Example 6 in in vitro cell lines. The specific experiment was to transfect the expression vector of cMSC-GFP in Example 6 into normal bladder mucosal epithelial cell line (SVHUC1), bladder cancer cell line (T24, UMUC3) and cervical cancer cell line (HeLa) cells, and collect 10 cells from each group of cells after 48 hours. 4 The proportion of GFP-expressing cells in each group of cells was analyzed by flow cytometry. The experimental results showed that compared with the normal cell SVHUC1, the cancer cells T24, UMUC3 and HeLa transfected with the optimized cMSC (gene circuit in Example 6) expressed 129.6 times, 117.8 times and 132.2 times of GFP, respectively, indicating that cMSC containing both the self-cleavage system and the expression amplification system has a higher activation rate than cMSC containing only the self-cleavage system ( Fig.13 ).

[0270] (2) In mice

[0271] Next, we studied the further application of cMSC in vivo. The efficiency of cMSC (cMSC in Example 6) was determined in a human xenograft tumor mouse model mediated by adeno-associated virus (AAV). Fig.14 ) and GFP as target genes in the constructed models. We constructed human xenograft tumor mouse models using U2OS and T24 cells, respectively, expressing low and high levels of endogenous c-MYC ( Fig.14 a).

[0272] Packaging of AAV virus: To obtain cMSC-driven GFP-expressing virus, HEK293T cells were co-transfected with cMSC-GFP expression plasmid, AAV serotype plasmid, and helper plasmid using the Lipo3000 transfection kit. 24 hours after transfection, cells in the cell culture medium were collected and centrifuged at 4000rpm for 15min. The supernatant was discarded, and the microspheres were resuspended in cell lysis buffer and frozen and thawed three times in a dry ice / ethanol bath. The cell lysate was centrifuged at 4,000rpm for 20min. Contaminating DNA in the supernatant was removed by adding benzonase and incubated at 37°C for 30min. The crude virus preparation was loaded onto the iodine glycol density gradient and spun at 60,000rpm for 90min using a Beckman Ti70 rotor. After centrifugation, 3-4ml of the crude virus preparation was collected from the 40%-60% layer and connected to a 10ml syringe with an 18-gauge needle. The crude virus solution was concentrated to 200-250 μl using an Amicon Ultra15 centrifugal filter (100 kDa), washed once with 8 ml PBS, and concentrated to an appropriate volume. Aliquots were stored at -80°C until use. The cMSC-driven expression virus was packaged into the AAV-2 serotype.

[0273] To determine the expression efficiency of cMSC-GFP in mice, 1×10 7 cells (T24 cells: U2OS cells 1:1). Then, 100 μl of AAV suspension was injected intratumorally 10 days after tumor formation. Seven days later, tumor tissues were collected for frozen sections, and the expression levels of the corresponding fluorescent proteins were observed under a confocal microscope.

[0274] It is noteworthy that after transfection with AAV-mediated cMSCs, the GFP activity of tumor tissues from T24 cells was 12.6 times that from U2OS cells, indicating that cMSCs can sense different endogenous c-MYC expressions in tumor tissues and drive different levels of target gene GOI expression accordingly ( Fig.14 b), and observation under a confocal microscope revealed that the fluorescence intensity of T24 cell tumor tissue was significantly stronger than that of U2OS cell tumor tissue ( Fig.14 c).

[0275] (3) Organoids

[0276] To further demonstrate the value of cMSC (cMSC in Example 6) in clinical application and clinical transformation, we studied the efficiency of cMSC in organoids. Three organoids were used to evaluate the effectiveness of cMSC, including one normal organoid derived from normal bladder mucosal epithelium (organoid-N) and two bladder cancer organoids derived from early (organoid-BC1) and late (organoid-BC2) bladder cancer patients. The expression level of endogenous c-MYC in organoids was quantified by qPCR ( Fig.15 a).

[0277] Experimental procedures: Packaging of AAV virus: To obtain cMSC-driven GFP-expressing virus, HEK293T cells were co-transfected with cMSC-GFP expression plasmid, AAV serotype plasmid and helper plasmid using Lipo3000 transfection kit. 24 hours after transfection, cells in cell culture medium were collected and centrifuged at 4000rpm for 15min. The supernatant was discarded, and the microspheres were resuspended in cell lysis buffer and frozen and thawed three times in a dry ice / ethanol bath. The cell lysate was centrifuged at 4,000rpm for 20min. Contaminating DNA in the supernatant was removed by adding benzonase and incubated at 37°C for 30min. The crude virus preparation was loaded onto the iodine glycol density gradient and spun at 60,000rpm for 90min using a Beckman Ti70 rotor. After centrifugation, 3-4ml of crude virus preparation was collected from the 40%-60% layer and connected to a 10ml syringe with an 18-gauge needle. The crude virus was concentrated to 200-250 μl using an Amicon Ultra15 centrifugal filter (100 kDa), washed once with 8 ml PBS, and concentrated to an appropriate volume. Aliquots were stored at -80°C until use. The cMSC-driven expression virus was packaged into the AAV-2 serotype. Fresh bladder cancer tumors and normal urothelial specimens were washed three times in PBS containing nystatin 50 μg / mL, streptomycin 500 μg / mL, and penicillin 500U, cut into small pellets, and incubated with 1 mL TrypLE at 37°C for 45 minutes. Undigested tissue was removed using a 70 μm cell strainer and the cells were pelleted by centrifugation. The collected cells were resuspended in complete medium mixed with a 1:2 volume of Matrigel matrix (BD Biosciences, Cat#356234). The cells in the droplets (10,000 / 30 μl) were plated in a 48-well plate. Complete medium was added after Matrigel polymerization, and then cultured at 37°C. When the organoids were ready, we sequentially added AAVs that delivered cMSC-driven GFP expression to the culture medium, and observed the expression of GFP in the organoid tissues using confocal microscopy 7 days later.

[0278] The experimental results are shown in Fig.15b. As expected, cMCS showed relatively high GFP expression (4.2 times) in organoid BC2, and endogenous c-MYC expression was higher than that in organoid BC1. Importantly, cMCS had almost no GFP-driven expression in organoid-N. It can be seen that the gene circuit of the present invention can be distinguished in organoids with different c-MYC expression doses, and the expression of the target gene can be driven in a controlled manner. In normal bladder organoid N with low c-MYC expression, the target gene GFP is basically not expressed; in early bladder cancer organoid BC1, c-MYC is relatively moderately expressed, and the target gene GFP is expressed in small amounts; in late bladder cancer organoid BC2, c-MYC is highly expressed, and the target gene GFP is also highly expressed, which can distinguish the physiological expression and pathological expression of c-MYC oncogenes and achieve precise intervention.

[0279] Example 8 Tumor immunotherapy using a therapeutic system containing cMSCs with different target genes

[0280] To determine the efficiency of cMSC-driven expression of different target genes - tumor immune activating factors, triggering T cell-mediated specific tumor immunotherapy, we established a humanized mouse model and established four different cMSCs, which were packaged with the delivery vector AAV, and four different cMSC-driven target genes: dual anti-CD3 / CD28 scFv expression (AAV1), IL-21 expression (AAV2), CCL5 expression (AAV3), anti-PD1 expression (AAV4) ( Fig.16 Left, where the dual anti-CD3 / CD28 scFv is abbreviated as STE in the figure).

[0281] The complete structure of the four cMSCs is shown in Fig.19 The target genes GOI are tumor immune activation dual antibody CD3 / CD28 scFv (STE), IL-21, CCL5, and anti-PD1.

[0282] The oncogene activating receptor contains a strong transcription activator binding site (binding site) (not shown in the figure), an oncogene activating promoter (c-MYC-activator), a target gene (GOI), a self-hydrolyzed polypeptide (P2A), a strong transcription activator (KLFa), and an aRNA-BS sequence in the self-cleaving system arranged in cis.

[0283] The oncogene inhibitory receptor contains an oncogene inhibitory promoter (c-MYC-activator) and a cis-arranged aRNA sequence in a self-cleaving system. The oncogene activating promoter and the oncogene inhibitory promoter are located in the same expression vector.

[0284] AAV was injected into mouse tumors and tumor volume was monitored. The specific experimental steps were as follows: 5-week-old NSG mice were selected and 1×10 7 cells (T24 cells). Seven days after tumor formation, human primary T cells were intravenously injected into tumor-bearing NSG mice, and that day was designated as day 0. AAV vectors were used to encode the expression of different parts of multiple cMSC-driven CIFs, and different AAV suspensions were infiltrated into the tumor periphery by intratumoral injection in a manner similar to the "exogenous administration mode". Five different AAVs were packaged and used, including cMSC-driven dual anti-CD3 / CD23 scFv expression (AAV1), IL-21 expression (AAV2), anti-PD1 expression (AAV3), and CCL5 expression (AAV4). Subsequently, AAV was injected intratumorally into mouse tumors, and tumor volume was continuously monitored. In the transplanted tumor mouse model, the height × width × length of the tumor was measured using a vernier caliper and recorded as mm3 until day 23. Compared with control mice infused with T cells only, the tumor volume growth of tumor-bearing mice infected with the above-mentioned AAV-mediated cMSC-driven combined immune regulatory factor expression and T cell infusion was significantly inhibited ( Fig.17 , Fig.18 ). The tumor immunotherapy efficiency of mice in the AAV1 suspension (AAV-STE) infection group, AAV1, 2, 3 suspension (AAV-SIC) infection group, and AAV1, 2, 3, 4 suspension (AAV-SICP) infection group were statistically significant, with average volume reductions of 65%, 86%, and 92%, respectively. These data indicate that the cMSC-based therapeutic system of the present invention can have a significant tumor treatment effect in animals, and when multiple tumor immune activation factors are administered simultaneously, the combined action of the combined immune stimulatory factors can induce a powerful anti-tumor immune response.

[0285] SEQ ID NO:12IL21:

[0286] ATGGCTGAAGTGAAAACGAGACCAAGGTCTAGCTCTACTGTTGGTACTTATGAGATCCAGTCCTGGCAACATGGAGAGG

[0287] ATTGTCATCTGTCTGATGGTCATCTTCTTGGGGACACTGGTCCACAAATCAAGTCCCAAGGTCAAGATCGCCACATGAT

[0288] TAGAATGCGTCAACTTATAGATATTGTTGATCAGCTGAAAAATTATGTGAATGACTTGGTCCCTGAATTTCTGCCAGCTCC

[0289] AGAAGATGTAGAGACAAACTGTGAGTGGTCAGCTTTTTCCTGTTTTCAGAAGGCCCAACTAAAGTCAGCAAATACAGG

[0290] AAACAATGAAAGGATAATCAATGTATCAATTAAAAAGCTGAAGAGGAAACCACCTTCCACAAATGCAGGGAGAAGACA

[0291] GAAACACAGACTAACATGCCCTTCATGTGATTCTTATGAGAAAAAACCACCCAAAGAATTCCTAGAAAGATTCAAATCA

[0292] CTTCTCCAAAAGATGATTCATCAGCATCTGTCCTCTAGAACACACGGAAGTGAAGATTCCTGAGGATCTAACTTGCAGTT

[0293] GGACACTATGTTACATACTCTAATATAGTAGTGAAAGTCATTTCTTTGTATTCCAAGTGGAGGAGCCCTATTAAATTATATA

[0294] AAGAAATA

[0295] SEQ ID NO:13CCL5:

[0296] ATGAAGGTCTCCGCGGCAGCCCTCGCTGTCATCCTCATTGCTACTGCCCTCTGCGCTCCTGCATCTGCCTTCCCATATTCC

[0297] TCGGACACCACACCCTGCTGCTTTGCCTACATTGCCCGCCCACTGCCCCGTGCCCACATCAAGGAGTATTTCTACACCAG

[0298] TGGCAAGTGCTCCAACCCAGCAGTCGTCTTTGTCACCCGAAAGAACCGCCAAGTGTGTGCCAACCCAGAGAAGAAATG

[0299] GGTTCGGGAGTACATCAACTCTTTGGAGATGAGCTAG

[0300] SEQ ID NO:14Anti-PD1:

[0301] ATGCAGGTGCAGCTCGTAGAGAGCGGGGGAGGTGTCGTTCAGCCAGGGAGGAGTCTGCGGCTGGACTGCAAAGCCTC

[0302] CGGGATTACTTTCTCAAACAGCGGGATGCACTGGGTGAGGCAGGCTCCCGGAAAGGGCCTCGAGTGGGTGGCGGTAAT

[0303] ATGGTACGACGGGAGCAAACGCTACTACGCAGACAGTGTGAAAGGAAGGTTCACTATTTCTCGCGACAATTCAAAGAA

[0304] CACCCTCTTCCTGCAGATGAACAGTCTGCGGGCAGAAGACACCGCTGTCTATTACTGTGCCACCAATGACGATTACTGG

[0305] GGCCAGGGTACCCTCGTGACCGTGTCTAGCGCCTCTACCAAAGGACCATCAGTTTTTCCTCTTGCTCCCTGCAGTCGCTC

[0306] AACCAGCGAGAGCACAGCAGCGCTGGGATGTCTGGTGAAGGATTATTTTCCTGAGCCCGTGACTGTGAGCTGGAATTC

[0307] AGGCGCCCTGACGTCCGGCGTCCATACATTCCCAGCGGTACTTCAAAGTAGCGGGTTGTACTCTCTCTCTAGCGTGGTAA

[0308] CCGTACCGAGCTCCTCCCTGGGGACGAAAACGTATACATGTAATGTCGATCACAAACCATCTAACACAAAAGTGGACAA

[0309] ACGCGTTGAGTCCAAGTATGGCCCTCCATGCCCACCCTGCCCCGCACCGGAGTTTCTGGGCGGGCCCAGTGTCTTTCTG

[0310] TTCCCACCGAAGCCTAAGGACACGTTGATGATCTCAAGAACACCTGAAGTCACCTGCGTAGTCGTGGACGTTTCTCAGG

[0311] AGGATCCCGAGGTCCAATTCAATTGGTACGTTGATGGAGTGGAGGTCCACAACGCAAAGACAAAGCCGCGCGAAGAAC

[0312] AGTTCAATTCTACTTACCGCGTTGTTAGCGTGCTGACTGTGCTCCACCAAGACTGGCTGAATGGTAAGGAGTATAAGTGC

[0313] AAGGTGAGCAATAAGGGATTGCCATCTAGCATCGAAAAGACAATATCCAAAGCCAAGGGCCAACCACGAGAGCCACAA

[0314] GTGTACACGTTGCCTCCCTCACAAGAAGAGATGACCAAGAATCAAGTGAGCCTCACTTGCCTGGTCAAGGGATTCTACC

[0315] CTTCTGATATCGCAGTGGAGTGGGAGTCCAATGGACAGCCCGAGAACAACTACAAGACAACACCCCCAGTGCTGGATT

[0316] CCGACGGCTCATTCTTCTTGTATAGCCGGCTGACAGTGGACAAGAGCAGGTGGCAGGAAGGAAATGTCTTCTCCTGCTC

[0317] CGTGATGCACGAGGCCCTCCACAACCACTACACTCAGAAATCTCTCTCTCTTTCACTCGGTAAATAAGAGGGCAGAGGC

[0318] AGTCTGCTGACATGCGGTGACGTGGAAGAGAATCCCGGCCCTGAAATAGTGCTGACCCAGTCCCCCGCCACCCTCTCTC

[0319] TCTCACCCGGAGAGAGGGCAACTCTGTCCTGCAGGGCCTCCCAATCCGTAAGCAGCTATCTGGCTTGGTACCAGCAAAA

[0320] ACCCGGACAGGCACCCCGGCTGTTGATCTATGACGCCTCCAACCGAGCCACTGGCATCCCCGCCAGATTCTCCGGATCT

[0321] GGATCAGGGACTGATTTTACCCTGACTATCAGTTCTCTGGAACCTGAAGATTTTGCAGTTTATTATTGTCAGCAAAGCTCT

[0322] AACTGGCCAAGAACCTTTGGCCAGGGCACGAAGGTCGAGATAAAAACTGTCGCGGCCCCAAGCGTCTTTATCTTTCCG

[0323] CCGTCTGATGAACAGCTGAAATCAGGGACCGCCTCTGTGGTGTGTCTGCTGAACAACTTCTACCCAAGGGAAGCTAAG

[0324] GTGCAATGGAAAGTAGACAATGCCTTGCAGAGCGGCAACTCTCAGGAGAGCGTAACCGAACAGGATAGTAAGGATTCA

[0325] ACTTACAGTCTGAGCTCTACCCTGACTCTGAGTAAGGCCGATTACGAGAAGCATAAAGTCTACGCATGCGAGGTCACAC

[0326] ATCAAGGTCTTTCATCTCCCGTGACAAAGTCCTTTAATCGAGGGGAATGCTAA

[0327] SEQ ID NO:15antiCD3 / CD28 scFv:

[0328] ATGCAAGTGCAGCTTCAGCAGAGCGGCGCTGAGCTGGCCCGGCCCGGGGCCTCTGTGAAAATGAGCTGCAAGGCTTCC

[0329] GGTTACACCTTTACAAGGTACACAATGCACTGGGTGAAGCAGCGGCCAGGGCAGGGGCTCGAGTGGATCGGCTACATA

[0330] AACCCATCTCGGGGATATACAAACTACAATCAAAAGTTCAAAGACAAGGCCACACTGACAACGGACAAGTCAAGCAGC

[0331] ACAGCTTACATGCAACTGAGCTCTCTGACATCCGAGGATAGCGCCGTTTACTATTGCGCCAGATACTATGATGACCACTAT

[0332] TGCTTGGACTACTGGGGACAGGGAACAACCCTCACAGTTAGCTCCGGCGGGGGGGGCAGTGGAGGTGGAGGATCTGG

[0333] GGGCGGCGGTAGTCAGATCGTCCTCACACAGTCTCCGGCCATAATGTCCGCCTCCCCCGGAGAGAAGGTTACTATGACA

[0334] TGTTCCGCATCTTCCTCTGTGTCATATATGAATTGGTACCAGCAGAAGAGTGGCACCTCTCCTAAACGCTGGATTTACGAT

[0335] ACCTCTAAACTGGCGTCCGGGGTGCCTGCACATTTCCGCGGATCCGGCTCCGGTACGAGTTATTCACTCACAATATCTGG

[0336] AATGGAGGCCGAAGATGCCGCTACTTACTACTGCCAACAATGGTCAAGCAACCCCTTCACTTTCGGGAGCGGGACAAA

[0337] GCTGGAGATCAACCACCATCATCATCACCATCATGCAGGTATGGCCTCCTCTGGGTATGTCCTCCAGGCGGAGCTTCCC

[0338] CCTCAACTGAGAACTCAAGTCAGCTGGACTTCGAAGATGTATGGAATTCTTCCTATGGTGTGAATGATTCCTTCCCAGAT

[0339] GGAGACTATGATGCCAACCTGGAAGCAGCTGCCCCCTGCCACTCCTGTAACCTGCTGGATGACTCTGCACTGCCCTTCT

[0340] TCATCCTCACCAGTGTCCTGGGTATCCTAGCTAGCAGCACTGTCCTCTTCATGCTTTTTCAGACCTCTCTTCCCGCTGGCAGC

[0341] TCTGCCCTGGCTGGCCTGTCCTGGCACAGCTGGCTGTGGGCAGTGCCCTCTTCAGCATTGTGGTGCCCGTCTTGGCCCC

[0342] AGGGCTAGGTAGCACTCGCAGCTCTGCCCTGTGTAGCCTGGGCTACTGTGTCTGGTATGGCTCAGCCTTTGCCCAGGCTT

[0343] TGCTGCTAGGGTGCCATGCCTCCCTGGGCCACAGACTGGGTGCAGGCCAGGTCCCAGGCCTCACCCTGGGGCTCACTG

[0344] TGGGAATTTGGGGAGTGGC

[0345] Note: The other partial sequences in cMSC in this example are the same as the gene expressing GFP in cMSC in Example 6, and the only difference is the target gene sequence. The target gene sequence in Example 6 is the GFP sequence, and in this example they are dual anti-CD3 / CD28scFv (STE), IL-21, CCL5, and anti-PD1.

[0346] Although the present invention has been described with reference to the current preferred embodiments, those skilled in the art should understand that the above-mentioned preferred embodiments are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention are included in the scope of protection of the present invention.

Claims

1. A gene circuit that can distinguish between physiological and pathological gene expression, It is characterized in that Contains the following components: (1) An oncogene activating receptor for promoting the expression of a target gene, comprising: (a) an activating promoter of an oncogene, wherein the activating promoter of an oncogene comprises at least a DNA sequence specifically binding to an oncogene protein and a promoter core sequence for transcriptional activation arranged in cis; and (b) a target gene, wherein the target gene comprises at least a CDS sequence for expression of the target gene and a binding sequence for a target gene inhibitory element arranged in cis; (2) An oncogene inhibitory receptor for inhibiting the expression of a target gene, comprising: (a) an oncogene inhibitory promoter, wherein the oncogene inhibitory promoter comprises at least a DNA sequence to which an oncogene protein specifically binds and a promoter core of transcriptional inhibition arranged in cis; and (b) Repressive elements that inhibit the expression of target genes.

2. The gene circuit according to claim 1, It is characterized in that The oncogene is selected from transcription factor genes; preferably, the oncogene is selected from one or more of c-MYC, N-MYC, L-MYC, E2F1, E2F2, E2F3, CREB, NF-κB, STAT, AP-1, bzip and HMG.

3. The gene circuit according to claim 1, It is characterized in that The target gene is selected from tumor immune activation cytokine genes, immune activation receptor / ligand genes, immune activation antibody genes, cytotoxic protein genes, or one or more combinations thereof of functional fragments; Preferably, the target gene is selected from CCL5, anti-PD1, anti-CTLA-4, IL-21, IL-2, IL-15, IL-7, IL-18, IL-12, GM-CSF, OX40L, anti-OX40, IFN-γ, TNF-α, CD137, anti-CD3, anti-CD28, or one or more combinations thereof of functional fragments; More preferably, the target gene is selected from a combination of anti-CD3 and anti-CD28; More preferably, the target gene is selected from a combination of anti-CD3-scFv and anti-CD28-scFv.

4. The gene circuit according to claim 1, It is characterized in that The inhibitory element is selected from one or more of siRNA, shRNA, miRNA, CRISPR-Cas9, CRISPR-Cas12a, CRISPR-Cas12j, CRISPR-Cas12f, CRISPR-Cas13a, CRISPR-Cas13b and CRISPR-Cas13d.

5. The gene circuit according to claim 1, It is characterized in that The inhibitory element is aRNA; the gene sequence of the aRNA is located at the 3' end of the inhibitory promoter, and contains a hammerhead ribozyme region at the 3' end and a miRNA at the 5' end; In the oncogene activating promoter, the binding sequence of the target gene inhibitory element is an aRNA-binding site; the gene sequence of the aRNA-binding site is located at the 3' end of the target gene CDS sequence, and contains a hammerhead ribozyme region at the 5' end and a miRNA binding sequence at the 3' end; After the transcribed aRNA and aRNA-binding site complement each other, they can degrade the mRNA of the target gene, thereby inhibiting the expression of the target gene.

6. The gene circuit according to claim 1, It is characterized in that The oncogene activation receptor also contains a target gene expression amplification system; the target gene expression amplification system consists of a gene sequence of a strong transcription activator and a binding site of the strong transcription activator; the gene sequence of the strong transcription activator is connected to the 3' end of the target gene through a gene sequence of a self-hydrolyzed polypeptide; the binding site of the strong transcription activator is located at the 5' end of the activation promoter of the oncogene.

7. The gene circuit according to claim 6, It is characterized in that The strong transcription activator is composed of one or more of KLF6, VP64, VP16, VPR, or partial domains thereof; Preferably, the strong transcriptional activator consists of partial domains of KLF6 and VP64.

8. The gene circuit according to claim 6, It is characterized in that The self-hydrolyzable polypeptide is selected from one or more of T2A, P2A, E2A and F2A.

9. The gene circuit according to claim 1, It is characterized in that The oncogene activating receptor and the oncogene inhibiting receptor may be located in the same gene circuit or in different gene circuits.

10. mRNA produced by transcription of the gene circuit according to any one of claims 1 to 9.

11. A protein expressed by the gene circuit according to any one of claims 1 to 9.

12. An expression vector comprising the gene circuit of any one of claims 1 to 9; preferably, the vector is selected from one or more of a plasmid, a phagemid, a cosmid, a baculovirus, a baculovirus shuttle vector, a bacterial expression vector, a yeast expression vector and a viral expression vector.

13. A therapeutic system, It is characterized in that Contains the gene circuit according to any one of claims 1 to 9, and a delivery vector.

14. The treatment system according to claim 13, It is characterized in that The delivery vector is selected from one or more of a viral delivery vector, a nanoparticle vector and a vesicle; Preferably, the nanoparticle carrier is selected from liposomes and virus-like particles; Preferably, the viral delivery vector is selected from an adeno-associated viral vector, a chimeric adeno-associated viral vector, an adenoviral vector, a retroviral vector, a lentiviral vector, a DNA viral vector, a herpes simplex viral vector, a baculoviral vector, or a mutant or derivative thereof.

15. The treatment system according to claim 13, It is characterized in that The administration method of the therapeutic system is one or more of in situ injection into the tumor, in situ perfusion, oral administration, inhalation, subcutaneous injection, intramuscular injection and intravenous injection; preferably, the administration method of the therapeutic system is in situ injection into the tumor or in situ perfusion.

16. Use of the gene circuit according to any one of claims 1 to 9, or the mRNA according to claim 10, or the protein according to claim 11, or the expression vector according to claim 12 in disease diagnosis or treatment.

17. The use according to claim 16, It is characterized in that The disease is selected from tumors.